Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy.
Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Clin Exp Rheumatol. 2024 May;42(5):947-960. doi: 10.55563/clinexprheumatol/166dsf. Epub 2024 May 14.
New evidence from 2023 has slightly shifted some perspectives on rheumatoid arthritis (RA) management. Glucocorticoids have reaffirmed their role as bridging therapy, while novel studies on JAK inhibitors have examined efficacy, mechanism of action, and their potential in high-risk populations, bolstering our understanding with real-world data.Additionally, among treatment strategies, achieving low disease activity has emerged as comparable to achieving remission in the long term, and new insights have been gained regarding tapering both biological and conventional synthetic DMARDs. Furthermore, novel approaches have been proposed for managing difficult-to-treat RA and pre-RA. In this paper, the reviewers aim to present the most relevant studies published during the last year in the field of RA management.
2023 年的新证据略微改变了人们对类风湿关节炎（RA）管理的一些看法。糖皮质激素再次确认了它们作为桥接治疗的作用，而关于 JAK 抑制剂的新研究则检查了它们在高危人群中的疗效、作用机制及其潜力，为我们提供了真实世界数据的支持。此外，在治疗策略中，实现低疾病活动度已经与长期达到缓解一样重要，并且在减少生物制剂和传统合成 DMARDs 方面也有了新的认识。此外，还提出了治疗难治性 RA 和预 RA 的新方法。在本文中，评审员旨在介绍过去一年中在 RA 管理领域发表的最相关研究。
